Brief: Brain Biotech Signs Exclusive Pharma Licensing Agreement With Akribion For Up To EUR 92.3 Million Milestone Fees Plus Royalties
31/10/2024 18:13
Oct 31 (Reuters) - BRAIN Biotech AG BNNn.DE :
* EQS-ADHOC: BRAIN BIOTECH AG SIGNS EXCLUSIVE PHARMA
LICENSING
AGREEMENT FOR G-DASE E® CRISPR-CAS TECHNOLOGY WITH AKRIBION
THERAPEUTICS GMBH FOR UP TO EUR 92.3 MILLION MILESTONE FEES PLUS
ROYALTIES
* BRAIN BIOTECH AG - NON-PHARMA RELATED PROPRIETARY CRISPR
RIGHTS
REMAIN WITH BRAIN FOR COMMERCIALIZATION IN ITS CORE BUSINESS
Source text: ID:nEQ8r669Ca
Further company coverage: BNNn.DE
((Reuters.Briefs@thomsonreuters.com;))
Recent news on BRAIN Biotech AG
See all newsBrief: BRAIN Biotech 9M EBITDA EUR -1.6 Million
CEOs Lukas Linnig And Michael Krohn To Leave Co
Brief: Brain Biotech Signs Exclusive Pharma Licensing Agreement With Akribion For Up To EUR 92.3 Million Milestone Fees Plus Royalties
Brief: BRAIN Biotech 9M Adj. EBITDA at EUR -1.2 Million
Europe Research Roundup: AB Foods, Bunzl, Barratt